Reprogramming the tumor microenvironment: endowing T with the ability to degrade the extracellular matrix 2259469
Prashant S. Menon, Monish Kumar, Jayashree Kanagarajan, Yichen Zhan et autres
Abstract Introduction Despite the remarkable success of chimeric antigen receptor (CAR) T cell therapy in hematological cancers, the clinical experience with solid tumors has not been encouraging. Preclinical and clinical data support that the tumor-specific extracellular matrix (ECM) presents a physical barrier …
us (code pays fourni par la source)
0 citations
The Journal of Immunology